McCall H, Adams N, Mason D, Willis J. What is chemsex and why is it important? BMJ. 2015;351:h5790. https://doi.org/10.1136/bmj.h5790 PMID: 26537832.
Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardò FP. When “Chems” meet sex: a booming phenomenon called “ChemSex”. Curr Neuropharmacol. 2017;15(5):762–70.
Sewell J, Miltz A, Lampe FC, Cambiano V, et al. Attitudes and Understanding of HIV Acquisition Risk (AURAH) Study Group. Polydrug use, chemsex drug use, and associations with sexual risk behavior among HIV-negative men who have sex with men attending sexual health clinics. Int J Drug Policy. 2017;43:33–43. https://doi.org/10.1016/j.drugpo.2017.01.001.
Curtis TJ, Rodger AJ, Burns F, Nardone A, Copas A, Wayal S. Patterns of sexualized recreational drug use and its association with risky behaviors and sexual health outcomes among men who have sex with men at London, UK: A comparison of industry studies conducted in 2013 and 2016. Sex Transm Infect. 2020; 96: 197–203.
Maxwell S, Shahmanesh M, Gafosc M. Chemsex behaviors in men who have sex with men: a systematic review of the literature. Int J Drug Policy. 2019;63:74–89.
Sewell J, Cambiano V, Speakman A, et al. Changes in chemsex and sexual behaviors over time, among a cohort of MSM in London and Brighton: results from the AURAH2 study. Int J Drug Policy. 2019;68:54–61.
Hampel B, Kusejko K, Kouyos RD, Boni J, Flepp M, Stöckle M, et al. Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV cohort study from 2007 to 2017. HIV Med. 2020;21:228–39.
Hinkin CH, Barclay TR. Drug use and medication adherence in people with HIV-1 infection. AIDS-related behavior. 2010;11:185–94.
Kalichman SC, Kalichman MO, Cherry C, et al. Intentional medication nonadherence due to interactive beliefs about toxicity in HIV-positive active drug users. J Acquire Immune Defic Syndr. 2015;70:503–9.
O’Halloran C, Rice B, White E, Desai M, Dunn DT, McCormack S, et al. Chemsex was not a barrier to self-reported daily adherence to PrEP among PROUD study participants. Int J Drug Policy. 2019;74:246–54. https://doi.org/10.1016/j.drugpo.2019.10.007.
Pufall EL, Kall M, Shahmanesh M, Nardone A, Gilson R, Delpech V, et al. Positive Voices Study Group. Sexualized drug use (“chemsex”) and high-risk sexual behaviors among HIV-positive men who have sex with men. Med. HIV. 2018;19(4):261–70. https://doi.org/10.1111/hiv.12574.
González-Baeza A, Dolengevich-Segal H, Pérez-Valero I, et al. Sexualized drug use (Chemsex) is associated with high-risk sexual behaviors and sexually transmitted infections in HIV-positive men who have sex with men: evidence from the U-SEX GESIDA 9416 study. of AIDS STD. 2018;32:112–8.
Pakianathan M, Whittaker W, Lee MJ, Avery J, Green S, Nathan B, Hegazi A. Chemsex and new HIV diagnosis among gay, bisexual, and other men who have sex with men attending sexual health clinics. Med. HIV. 2018. https://doi.org/10.1111/hiv.12629.
Guerras JM, Hoyos Miller J, et al. Association of sexualized drug use patterns with HIV/STI transmission risk in an Internet sample of men who have sex with men from seven European countries. Sexual behavior Arch. 2021;50:461–77.
Hibbert MP, Brett CE, Porcellato LA, Hope VD. Psychosocial and sexual characteristics associated with sexualised drug use and chemsex among men who have sex with men (MSM) in the UK. Sex Transm Infect. 2019;95(5):342–50.
Wilkerson JM, Di Paola A, Nieto D, Schick V, Latini DM, Braun-Harvey D, et al. Sexual Violence and Chemsex Among Substance-Using Sexual and Gender Minorities in Texas. Subst Use Abuse. 2021;56(14):2141–50. https://doi.org/10.1080/10826084.2021.1975743.
Finnerty F, Fitzpatrick C, Stockwell S, Richardson D. The Changing Face of Male Sexual Assault: Recreational Drug Use and Multiple Offenders. Sex Transm Infect. 2019;95(7):550.
Kumar S, Rao PS, Earla R, Kumar A. Drug interactions between antiretroviral therapies and drugs of abuse in anti-HIV systems. Expert Opin Drug Metab Toxicol. 2015;11:343–55.
Bracchi M, Stuart D, Castles R, Khoo S, Back D, Boffito M. Increased use of “party drugs” among people living with HIV on antiretroviral therapy: a patient safety concern. AIDS. 2015;29:1585–92.
Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet. 1998;352:1751–2.
Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Med Intern. 1999;159:2221–4.
Hales G, Roth N, Smith D. Possible lethal interaction between protease inhibitors and methamphetamine. Antivir Ther. 2000;5(1):19PMID:10846588.
Papaseit E, Vázquez A, Pérez-Mañá C, et al. Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV). Intensive Care Med. 2012;38:1239–40.
Kobayashi M, Takata Y, Goseki Y, et al. Sudden cardiac death induced by sildenafil and sexual activity in a seropositive patient with drug interaction, early cardiac repolarization and arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. 2015 Jan;20(179):421–3. https://doi.org/10.1016/j.ijcard.2014.11.090.
Hockenhull J, Murphy KG, Paterson S. An observed increase in γ-hydroxybutyrate-associated deaths in London: evidence suggesting a possible link with a concomitant increase in chemsex. Forensic Sci Int. 2017;270:93–7. https://doi.org/10.1016/j.forsciint.2016.11.039.
World Health Organization. Management of acute poisoning. Available at: https://www.who.int/substance_abuse/terminology/acute_intox/en/#:~:text=A%20transient%20condition%20following%20the,other%20psychophysiological%20functions%20and%20responses.
Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Classification of acute poisoning. J Toxicol Clin Toxicol. 1998;3:205–13.
Elian AA. A new method for detecting GHB in urine and its application to drug-facilitated sexual assault. Forensic Sci Int. 2000;109:183–7.
Pillai RM, Watson RR. In vitro immunotoxicology and immunopharmacology: studies on drugs of abuse. Toxicol Lett. 1990;53:269–83.
Stefanidou M, Loutsidou AC, Chasapis CT, Spiliopoulou CA. Immunotoxicity of cocaine and crack. Curr Drug Abuse Rev. 2011;4:95–7.
Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events of drug treatment of human immunodeficiency virus disease. Am J Med. 1996;101:34–40.
Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV/AIDS: the need for an integrated response. AIDS. 2019;33:1411–20.
Kendall CE, Wong J, Taljaard M, et al. A population-based, cross-sectional study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;14:161. https://doi.org/10.1186/1471-2458-14-161.
Hobkirk AL, Towe SL, Lion R, Meade CS. Primary and secondary prevention of HIV in people with severe mental illness: recent findings. Curr HIV/AIDS Rep. 2015;12:406–12.
Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on the reference standard in an HIV-positive patient population. Psychosome Med. 2008;70:505–11.
Blank MB, Himelhoch SS, Balaji AB, et al. A multisite survey of HIV prevalence with rapid testing in mental health settings. Am J Public Health. 2014;104:2377–84.
Nedelcovych MT, Manning AA, Semenova S, Gamaldo C, Haughey NJ, Slusher BS. The psychiatric impact of HIV. ACS Chem Neurosci. 2017;8:1432–4.
Hartzler B, Dombrowski F, Crane HM, et al. Prevalence and predictors of substance use disorders among people enrolled in HIV care in the United States. AIDS-related behavior. 2017;21:1138–48.
Fuster-RuizdeApodaca MJ, Castro-Granell V, Garin N, et al. Prevalence and patterns of illicit drug use among people living with HIV in Spain: a cross-sectional study. PLoS One. 2019;14(6):e0211252.
Goodlet KJ, Zmarlicka MT, Peckham AM. Drug interactions and clinical considerations with the co-administration of antiretrovirals and psychotropic drugs. CNS spectrum. 2019;24:287–312.
Berg RC, Amundsen E, Haugstvedt Å. Links between chemsex and reduced mental health in Norwegian MSM and other men: results from a cross-sectional clinical survey. BMC Public Health. 2020;20(1):1785. https://doi.org/10.1186/s12889-020-09916-7.
Fight against the chemsex phenomenon. Secretary of the National AIDS Control Plan. Ministry of Health. 2020 available at https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/chemSex/docs/CHEMSEX._ABORDAJE.pdf
Brook G, Church H, Evans C, Jenkinson N, McClean H, Mohammed H, et al. 2019 UK national guideline for consultations requiring the taking of a sexual history: clinical effectiveness group British Association for Sexual Health and HIV. Int J MST AIDS. 2020;31(10):920–38. https://doi.org/10.1177/0956462420941708.